New malaria drug shows promise in severe cases
NCT ID NCT04675931
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new intravenous drug called cipargamin in 254 adults and children with severe malaria. The goal was to find a safe and effective dose that quickly clears the malaria parasite, especially in areas where standard treatments are becoming less effective. Researchers measured how well the drug reduced parasite levels and improved clinical outcomes within 48 hours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cipargamin (KAE609)
What this could lead to
If successful, cipargamin could offer a new treatment option for severe malaria, especially where current drugs are losing effectiveness due to resistance.
What could go wrong
This is a Phase 2 trial with only 254 participants, so results are preliminary. The drug may not prove safe or effective in larger studies, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Burkina Faso, 2208, Burkina Faso
-
Novartis Investigative Site
Ouagadougou, Burkina Faso
-
Novartis Investigative Site
Abidjan, 13BP972, Côte d’Ivoire
-
Novartis Investigative Site
Agboville, BP 154, Côte d’Ivoire
-
Novartis Investigative Site
Kinsasha, Democratic Republic of Congo, BP 7948, Democratic Republic of the Congo
-
Novartis Investigative Site
Siaya, 2300, Kenya
-
Novartis Investigative Site
Manhiça, Maputo Province, 1929, Mozambique
-
Novartis Investigative Site
Kigali, BP 4560, Rwanda
-
Novartis Investigative Site
Tororo, 10102, Uganda